Sensorimotor effects of pergolide, a dopamine agonist, in healthy subjects: a lateralized readiness potential study.
OBJECTIVE
The major purpose of the present study was to further elucidate dopaminergic modulation of sensorimotor processing in healthy human subjects.


METHODS
To more specifically analyze dopaminergic effects on premotor and motor stages of sensorimotor processing, lateralized readiness potentials (LRPs) were obtained. In a randomized double-blind crossover design, either 0.075 mg of the D1/D2 dopamine (DA) agonist pergolide or placebo were administered to 12 healthy male volunteers ranging from 19 to 25 years in age. The subjects performed a two-choice visual reaction time task. In addition to behavioral measures, such as response speed and error rate, stimulus-locked LRP (S-LRP) and response-locked LRP (LRP-R) latencies were determined. To better dissociate potential central and peripheral motor effects, measures of response dynamics and response-locked electromyogram (EMG-R) recordings were also obtained.


METHODS
Pergolide reliably enhanced speed of stimulus-related information processing as indicated by shorter S-LRP latencies while LRP-R latencies, reaction time, and indicators of response dynamics were not influenced by DA agonistic treatment. Furthermore, lower EMG-R amplitudes and an increased number of wrong-hand responses were observed under pergolide compared to placebo.


CONCLUSIONS
The results indicate that dopaminergic neurotransmission effectively modulates early perceptual and cognitive stages of information processing as suggested by neural network models of the functional role of prefrontal DA. The lack of an effect on aspects of motor processing may be due to a higher capacity of the nigrostriatal compared to the mesocortical DA system to compensate pharmacologically induced changes in dopaminergic activity.
Rammsayer
Thomas
T
Georg-Elias-Müller-Institut für Psychologie, Universität Göttingen, Gosslerstr. 14, 37073 Göttingen, Germany. trammsa@uni-goettingen.de
Stahl
Jutta
J
D000328:Adult; D003265:Contingent Negative Variation / Q000187:drug effects*; D004298:Dopamine / Q000502:physiology; D018491:Dopamine Agonists / Q000494:pharmacology; D004311:Double-Blind Method; D004576:Electromyography; D006801:Humans; D008297:Male; D009043:Motor Activity / Q000187:drug effects*; D010479:Pergolide / Q000494:pharmacology*; D011930:Reaction Time / Q000187:drug effects
D018491:Dopamine Agonists; D010479:Pergolide; D004298:Dopamine